Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BiomX Wants To Reverse The Focus Of Microbiome Therapy

Executive Summary

Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.

Advertisement

Related Content

Finance Watch: Scripps Research Models A New Way To Fund Translation
Antibiotic Development Question: Should A Phage Library Equal One Application?
How Intract Is Helping Shape Microbiome-Based Therapies
Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel